Dr. McArthur Discusses Subpopulation Data from coBRIM Trial in Advanced Melanoma

Grant McArthur, PhD
Published: Saturday, Nov 23, 2019



Grant McArthur, PhD, Melanoma Unit, Peter MacCallum Cancer Centre, discusses significant results from the final analysis of the coBRIM trial, which evaluated the 5-year survival data of cobimetinib (Cotellic) plus vemurafenib (Zelboraf) in patients with BRAF V600-mutated advanced melanoma.

In an analysis of subpopulations, McArthur says all patients did receive benefit from the combination versus monotherapy treatment. However, patients with an elevated lactate dehydrogenase (LDH) had less benefit in terms of long-term survival outcomes. Forty-three percent of patients with a normal LDH at baseline were alive at 5 years, while 16% with an elevated LDH remained alive. This is a striking difference, McArthur notes.


Grant McArthur, PhD, Melanoma Unit, Peter MacCallum Cancer Centre, discusses significant results from the final analysis of the coBRIM trial, which evaluated the 5-year survival data of cobimetinib (Cotellic) plus vemurafenib (Zelboraf) in patients with BRAF V600-mutated advanced melanoma.

In an analysis of subpopulations, McArthur says all patients did receive benefit from the combination versus monotherapy treatment. However, patients with an elevated lactate dehydrogenase (LDH) had less benefit in terms of long-term survival outcomes. Forty-three percent of patients with a normal LDH at baseline were alive at 5 years, while 16% with an elevated LDH remained alive. This is a striking difference, McArthur notes.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x